{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:46:37Z","timestamp":1792424797735,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8207130236"],"award-info":[{"award-number":["8207130236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113225","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:44:38Z","timestamp":1727678678000},"page":"113225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["External evaluation of tacrolimus population pharmacokinetic models in adult lung transplant patients: How to enhance the predictive ability of the model?"],"prefix":"10.1016","volume":"143","author":[{"given":"Lu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2024.113225_b0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.healun.2004.02.022","article-title":"Overview of tacrolimus-based immunosuppression after heart or lung transplantation","volume":"24","author":"Reichenspurner","year":"2005","journal-title":"J. Heart Lung Transpl."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0010","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0015","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1039\/D0FO00315H","article-title":"Citrus auraptene induces drug efflux transporter P-glycoprotein expression in human intestinal cells","volume":"11","author":"Nabekura","year":"2020","journal-title":"Food Funct."},{"issue":"10","key":"10.1016\/j.intimp.2024.113225_b0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr. Drug Metab."},{"issue":"11","key":"10.1016\/j.intimp.2024.113225_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15112580","article-title":"A physiologically based pharmacokinetic approach to recommend an individual dose of tacrolimus in adult heart transplant recipients","volume":"15","author":"Pei","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.intimp.2024.113225_b0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40262-023-01259-x","article-title":"A joint pharmacokinetic model for the simultaneous description of plasma and whole blood tacrolimus concentrations in kidney and lung transplant recipients","volume":"62","author":"Koomen","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0040","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/bcp.13083","article-title":"Comparative performance of oral midazolam clearance and plasma 4\u03b2-hydroxycholesterol to explain interindividual variability in tacrolimus clearance","volume":"82","author":"Vanhove","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113225_b0045","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/ajt.13309","article-title":"Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation","volume":"15","author":"Sikma","year":"2015","journal-title":"Am. J. Transpl."},{"issue":"3","key":"10.1016\/j.intimp.2024.113225_b0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","article-title":"Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation","volume":"51","author":"Monchaud","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.113225_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105448","article-title":"Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients","volume":"152","author":"Cai","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.113225_b0060","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","article-title":"Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review","volume":"59","author":"Kirubakaran","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0065","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1600-6143.2005.00870.x","article-title":"Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions","volume":"5","author":"Knoop","year":"2005","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.intimp.2024.113225_b0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clinbiochem.2019.05.003","article-title":"Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4\/5-related markers in rheumatoid arthritis patients","volume":"69","author":"Naito","year":"2019","journal-title":"Clin. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2024.113225_b0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0080","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s13318-022-00790-9","article-title":"Dual inhibition of CYP3A4 by voriconazole and clarithromycin influences tacrolimus pharmacokinetics: case series study","volume":"47","author":"Hirai","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0085","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1086\/516138","article-title":"Interactions between tacrolimus and antimicrobial agents","volume":"25","author":"Paterson","year":"1997","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113225_b0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.intimp.2024.113225_b0095","unstructured":"Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplantation, 2021, 12(1): 8-14, 28, doi: 10.3969\/j.issn.1674-7445.2021.01.002."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","article-title":"Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint","volume":"71","author":"Duffull","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113225_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.pa.32.040192.001153","article-title":"Population pharmacokinetics\/dynamics","volume":"32","author":"Sheiner","year":"1992","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113225_b0110","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","article-title":"Population pharmacokinetic modelling and Bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet?","volume":"55","author":"Brooks","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.intimp.2024.113225_b0115","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bcp.12830","article-title":"External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients","volume":"81","author":"Zhao","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113225_b0120","doi-asserted-by":"crossref","first-page":"1031969","DOI":"10.3389\/fphar.2022.1031969","article-title":"Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: a comparison of Michaelis-Menten and theory-based pharmacokinetic models","volume":"13","author":"Cai","year":"2022","journal-title":"Front Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113225_b0125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12361","article-title":"Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling","volume":"78","author":"St\u00f8rset","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113225_b0130","unstructured":"N.M.P. Administration, Domestic medical devices (registration) -- \u201cShanghai Instrument Registration 20192400305\u201d basic information, 2019. <https:\/\/www.nmpa.gov.cn\/datasearch\/search-info.html?nmpa=aWQ9NThmNTM5ZmUyNjhmYmVjOTQzN2UzOWU2MzAxOTU2ZWMmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTgzY2I2NmZlNjkwMjg1> (Accessed 04\/22 2024)."},{"issue":"1","key":"10.1016\/j.intimp.2024.113225_b0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bcp.13431","article-title":"External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients","volume":"84","author":"Mao","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113225_b0140","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bcp.13850","article-title":"Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus","volume":"85","author":"Zhang","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113225_b0145","article-title":"External evaluation of vancomycin population pharmacokinetic models at two clinical centers","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113225_b0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"Aaps J."},{"issue":"2","key":"10.1016\/j.intimp.2024.113225_b0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.intimp.2024.113225_b0160","unstructured":"Perl-speaks-NONMEM. <https:\/\/uupharmacometrics.github.io\/PsN\/> (Accessed 04\/22 2024)."},{"issue":"10","key":"10.1016\/j.intimp.2024.113225_b0165","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/jcph.2066","article-title":"Effects of voriconazole exposure on the pharmacokinetics of tacrolimus in lung transplantation patients, based on therapeutic drug monitoring data","volume":"62","author":"Chen","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113225_b0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13318-019-00591-7","article-title":"High variability of whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation","volume":"45","author":"Sikma","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacok."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0175","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","article-title":"Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation","volume":"59","author":"Sikma","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113225_b0180","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/FTD.0000000000000094","article-title":"Transplant patient classification and tacrolimus assays: more evidence of the need for assay standardization","volume":"36","author":"Agrawal","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.intimp.2024.113225_b0185","doi-asserted-by":"crossref","DOI":"10.1039\/C6JA00108D","article-title":"Turbulent flow chromatography in combination with HPLC-ICP-MS for high-throughput analysis of free, intact metal based drugs in biomedical samples","volume":"31","author":"Koellensperger","year":"2016","journal-title":"J. Anal. Spectrom."},{"issue":"4","key":"10.1016\/j.intimp.2024.113225_b0190","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jpba.2010.06.022","article-title":"Evaluation of the architect tacrolimus assay in kidney, liver, and heart transplant recipients","volume":"53","author":"Bazin","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.intimp.2024.113225_b0195","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.transproceed.2021.10.031","article-title":"CYP3a5 genetic polymorphism in Chinese population with renal transplantation: a meta-analysis review","volume":"54","author":"Cao","year":"2022","journal-title":"Transpl. Proc."},{"issue":"3","key":"10.1016\/j.intimp.2024.113225_b0200","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/cts.12956","article-title":"Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients","volume":"14","author":"Zhu","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.113225_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.intimp.2024.113225_b0210","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/FTD.0000000000000867","article-title":"Can we predict individual concentrations of tacrolimus after liver transplantation? Application and tweaking of a published population pharmacokinetic model in clinical practice","volume":"43","author":"Decrocq-Rudler","year":"2021","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.intimp.2024.113225_b0215","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0090-9556(25)07474-4","article-title":"Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance","volume":"21","author":"Piekoszewski","year":"1993","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.intimp.2024.113225_b0220","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01059398","article-title":"Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares","volume":"13","author":"Sheiner","year":"1985","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"12","key":"10.1016\/j.intimp.2024.113225_b0225","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/0003088-200847120-00003","article-title":"The enzymatic basis of drug-drug interactions with systemic triazole antifungals","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.113225_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106405","article-title":"Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: a semiphysiologically based population pharmacokinetic modeling approach","volume":"184","author":"Li","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2024.113225_b0235","article-title":"CYP3A5 genotype-dependent drug-drug interaction between tacrolimus and voriconazole in chinese kidney transplant patients","author":"Zhang","year":"2023","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2024.113225_b0240","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12882-023-03188-0","article-title":"Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation","volume":"24","author":"Nguyen","year":"2023","journal-title":"BMC Nephrol."}],"updated-by":[{"DOI":"10.1016\/j.intimp.2024.113923","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924017478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924017478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:54:48Z","timestamp":1740617688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924017478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":48,"alternative-id":["S1567576924017478"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113225","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External evaluation of tacrolimus population pharmacokinetic models in adult lung transplant patients: How to enhance the predictive ability of the model?","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113225"}}